An exciting biologic drug called brenetafusp is being studied, and showing real promise, in treating advanced cutaneous melanoma.
Health Professionals
RELATIVITY-048: Triplet Immunotherapy Shows Activity in Untreated Advanced Melanoma
As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall survival in the nonrandomized phase I/II RELATIVITY-048 trial, as reported by Paolo Antonio Ascierto, MD, of the Istituto Nazionale dei Tumori IRCCS in Naples, Italy, at the 2024 ASCO Annual Meeting.
Melanoma Brain Metastases: New Study Offers Insight for More Effective Cancer Treatment
For those living with advanced melanoma, brain metastases— malignant growths that occur when cancer cells travel to the brain—are particularly challenging to treat.
Dr Khushalani on Fixed-Dose Treatment Regimens in Advanced Melanoma
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the benefits and limitations of fixed-dose treatment regimens, such as the combination of fianlimab (formerly REGN 3767) and cemiplimab-rwlc (Libtayo) that is under investigation in the phase 3 HARMONY HEAD TO HEAD trial (NCT06246916) in patients with unresectable or metastatic melanoma.